ERYTECH Pharma announces that an independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the company’s Expanded Access Program (EAP) in Acute Lymphoblastic Leukemia (ALL) and recommended continuation of the program without modification
The post ERYTECH announces positive DSMB annual review of its Expanded Access Program in ALL appeared first on Erytech Pharma.